Table 3.

Univariable cox regression models for comparing groups 1 and 2; endpoint: biochemical recurrence and clinical progression. (For clinical progression follow-up data were available for 132 patients).

	Biochemical progression		Clinical progression
	HR (95% CI)	P value	HR (95% CI)	P value
Whole sample	0.15 (0.08–0.29)	<0.001	0.21 (0.08–0.6)	0.003
Low Gleason <7	0.16 (0.08–0.31)	<0.001	0.25 (0.08–0.8)	0.02
High Gleason ≥7	0.11 (0.01–0.86)	0.04	0.18 (0.02–1.6)	n.s.
R0	0.13 (0.03–0.48)	0.002	1.15 (0.1–13.4)	n.s.
R1	0.16 (0.75–0.32)	<0.001	0.15 (0.04–0.53)	<0.01
pT3a	n.s.	n.s.	n.s.	n.s.
pT3b	0.15 (0.08–0.29)	<0.001	0.26 (0.09–0.75)	0.013
pT4	0.22 (0.02–2.1)	n.s.	n.s.	n.s.